CD274 and neoplasm: In detail, an OS improvement in favor of atezolizumab was reported in the stage II-IIIA tumors with a PD-L1 tumor proportion score (TPS) > 1% and the benefit was greatest in the stage II-IIIA tumors with a PD-L1 TPS > 50%.